



Official Website



Scan to Download Digital List

Email overseas@yifanyy.com

Web www.yifanyy.com



YIFAN Pharmaceutical

Committed to becoming a new contributor of expertise in
the global pharmaceutical and health industry

• Biologics • Small Molecule • Herbal Medicine • Synbio

Striving to Eliminate Disease of Humans

Yifan Pharmaceutical is an innovative pharmaceutical enterprise focused on the health field. We have built a comprehensive production quality control and innovative research and development system that is in line with international standards, focusing on four major business areas: **Macromolecules, Small Molecules, Synthetic Biology, and Characteristic Herbal Medicine**. We actively promote the construction of a widely improved global commercial network, allowing high-quality domestic drugs to go out and introducing high-quality overseas drugs to help cure diseases.

~5000
Employees
Worldwide

50+
Countries and
Regions Covered

60+
Global
Subsidiaries

100+
Production
Lines

10+
Manufacturing
Sites

300+
IP

5
R&D
Centers

01 | Biological Product List 亿帆大分子产品

Novel Biologics | Biosimilar | Tool Enzyme

Marketed Novel Biological Product 已上市创新生物制品

Indication 适应症	Product Name 产品名	Target 靶点	Dosage Form & Strength 剂量和规格	Regulatory Approvals 注册批准日期
Chemotherapy-induced neutropenia (CIN) 化疗所致中性粒细胞减少症(CIN)	Efbemalenograstim alfa injection (Ryzneuta®) 艾贝格司亭α注射液（亿立舒®）	G-CSF	Subcutaneous injection in PFS; 1ml:20mg 水剂，预充针，皮下注射；1 mL：20 mg	中国NMPA: May. 2023 美国FDA: Nov. 2023 欧盟EMA: Mar. 2024 巴西ANVISA: Dec.2024

Novel Biological Products Under Development 在研创新生物制品

Indication 适应症	Product Name 产品名	Target 靶点	Dosage Form & Strength 剂量和规格	Remarks 备注
Alcoholic hepatitis (AH), Acute-on-chronic liver failure (ACLF), Acute graft versus host disease (aGVHD) 酒精性肝炎（AH）、慢加急性肝衰竭（ACLF）、急性移植术抗宿主病（aGVHD）	Recombinant human interleukin22-Fc fusion protein injection (F-652) 注射用重组人白介素22-Fc融合蛋白（F-652）	IL-22	Highest global status: Clinical trial II 全球最高研发阶段：临床II期	*Good safety profiles obtained from 200+ subjects in US, China and Australia *F-652 monotherapy or in combination with steroids shows a trend for improved efficacy in phase 2a studies *FDA granted the Orphan Drug Designation *200+美国、中国及澳大利亚受试者中获得良好的安全性数据 *F-652 单一疗法或与类固醇联合使用在 2a 期研究中显示出疗效改善的趋势 *FDA 授予孤儿药资格
Growth hormone deficiency 生长激素分泌不足所致的生长障碍	Recombinant human growth hormone-Fc fusion protein injection (F-899) 重组人生长激素-Fc融合蛋白注射液（F-899）	GH	Clinical trial Ia completed 完成临床Ia期	*Longer elimination half-life, supporting longer administration intervals (10/14 days) *更长半衰期，支持临床更间隔给药（10/14天）
Solid tumors (e.g. Bladder cancer) 实体瘤(如膀胱癌)	Recombinant human interleukin15-Fc fusion protein Injection (N-3C01) 重组人白介素15-Fc融合蛋白注射液（N-3C01）	IL-15	IND-enabling 支持新药临床实验申请的研究阶段	*Extended half-life enables less frequent dosing, enhancing patient adherence *Structure-guided fusion protein optimization maximizes both stability and therapeutic potency *更长半衰期，降低用药频次提升患者用药依从性 *融合蛋白分子结构设计优化，兼顾结构稳定和药物活性

Biosimilar Products Under Development

在研生物类似物

TA 治疗领域	Product Name 产品名称	Reference Drug 原研药/厂家	Status 状态	Pharmacopeia Compliance 药典合规性		Remarks 备注
				EP/USP	CP	
Growth hormone deficiency 生长激素分泌不足所致的生长障碍	Somatropin injection 生长激素注射液	Norditropin Novo Nordisk 诺泽诺和诺德	IND (China) Submitted 已提交IND（中国） API/BDP marketable API和BPD均可售	Y	Y	*Prokaryotic Expression Platform for Peptide Hormones Independently developed with streamlined and stable processes. Significantly improves yield while reducing production costs *In-House Synthesis of Key Raw Materials Side-chain raw materials synthesized internally to ensure quality control Mitigates supply chain risks and further lowers costs *High-Yield Engineered Bacterial Strains Fusion protein expression exceeds 35% of total bacterial protein *Proprietary Tool Enzymes Self-developed enzymes simplify purification and increase recovery rates *U.S. DMF Filing submitted: Somatropin (Growth Hormone) API, Insulin Glargine API
Diabetes 糖尿病	Insulin glargine injection *Long-acting insulin analogue 甘精胰岛素注射液 *长效胰岛素类似物	Lantus Sanofi 来得时 赛诺菲	IND (China) Submitted 已提交IND（中国） API marketable API可售	Y	Y	
	Insulin degludec injection *Ultralong-acting basal insulin analogue 德谷胰岛素注射液 *超长效基础胰岛素类似物	Tresiba Novo Nordisk 诺和达 诺和诺德	IND (China) Submitted 已提交IND（中国） API marketable API可售	Y	Y	
	Insulin aspart injection *Short acting insulin analogue 门冬胰岛素注射液 *短效胰岛素类似物	NovoRapid Novo Nordisk 诺和锐 诺和诺德	IND (China) Submitted 已提交IND（中国） API marketable API可售	Y	Y	
Osteoporosis 骨质疏松	Teriparatide injection 特立帕肽注射液	Forteo Eli Lilly 复泰奥 礼来	Pre-clinical completed 已完成非临床试验 API marketable API可售	Y	Y	
Weight Management Type II Diabetes 体重管理 II型糖尿病	Semaglutide Injection 司美格鲁肽注射液	Ozempic Novo Nordisk 诺和泰 诺和诺德	API marketable API可售	Y	Y	 *已建立自主研发的原核肽类激素生产技术平台，工艺步骤精简、稳定，提高产量、降低成本 *关键原材料侧链为内部合成，质量可控，供应风险和生产成本降低 *高表达工程菌株：表达的融合蛋白占菌体总蛋白的35%以上 *自主开发工具酶，降低纯化困难，提高回收率 *生长激素、甘精胰岛素原料药已在美国DMF备案
	Liraglutide Injection 利拉鲁肽注射液	Victoza Novo Nordisk 利鲁平 诺和诺德	API marketable API可售	Y	Y	

Marketable Tool Enzymes

可售工具酶

Product 产品名称	Expression System 表达体系	Cleavage/Digestion 酶切特点	Usage 用途	Potency 酶活
Recombinant trypsin 重组胰蛋白酶	E. coli. 大肠杆菌	Precise Cleavage at Lysine and Arginine C-terminal Peptide Bonds: Highly specific proteolytic activity exclusively targeting peptide bonds C-terminal to lysine (K) and arginine (R) residues 特异切割赖氨酸（K）以及精氨酸（R）C末端肽键	*Alternative therapy for indigestion *Food Industry: Protein depressant *Biotech/Pharmaceutical Industries: Enzymatic digestion and gene splicing *临床：替代治疗（消化不良） *食品工业：蛋白质降解剂 *生物工程/制药：蛋白质酶切、基因剪切	Specific Activity 比活 ≥ 5000 U/mg
Recombinant carboxypeptidase-B (CPB) 重组胰蛋白酶		Exclusively hydrolyses peptide bonds at the N-terminus of C-terminal basic amino acids (lysine K, arginine R, histidine H) in proteins 专一水解蛋白质C-末端碱性氨基酸（赖氨酸K、精氨酸R、组氨酸H）的氨基酸	*Biotech/Pharmaceutical Industries: Enzymatic digestion and enzyme-induced synthesis *生物工程/制药：蛋白质酶切，酶促合成	Specific Activity 比活 ≥ 80 U/mg
Recombinant Lys-C 重组赖氨酰内切酶		Highly Specific Lysyl Peptide Bond Cleavage: Exclusive enzymatic digestion of peptide bonds at DK and PK sequences (Lys at P1 position). Complete specificity for lysyl-endopeptidase activity with no observed off-target hydrolysis 特异性针对赖氨酰肽键酶切，包含含DK、PK序列的完全特异酶切	*Biotech/Pharmaceutical Industries: Enzymatic digestion and enzyme-induced synthesis *生物工程/制药：蛋白质酶切，酶促合成	Specific Activity 比活 ≥ 20 U/mg
Recombinant bovine enterokinase (light chain) *liquid 重组牛肠激酶（轻链）*液体	Yeast 酵母菌	Specific hydrolysis at DDDDK ↓ X motifs (cleavage C-terminal to lysine in tetra-aspartate sequences) 可以切割含有四个天冬氨酸的赖氨酸羧基端肽键（DDDDK）	*Haemorrhage prevention and treatment *Biotech/Pharmaceutical Industries: Enzymatic digestion *临床：预防或治疗出血 *生物工程/制药：蛋白质酶切	Specific Activity 比活 5.0 U/μL*
Recombinant Kex-2 Protease 重组双碱基内切酶		Specifically recognizes and cleaves carboxyl-terminal peptide bonds of dibasic amino acid motifs, including arginine-arginine (RR) and lysine-arginine (KR) 特异性识别和切割精氨酸-精氨酸（RR）、赖氨酸-精氨酸（KR）等双碱基氨基酸羧基端肽键	*Biotech/Pharmaceutical Industries: Enzymatic digestion *生物工程/制药：蛋白质酶切	Specific Activity 比活 ≥ 8 U/mg

02 | Small Molecule
Product List 亿帆小分子产品

Formulation | Herbal Medicine | API | Excipient | Intermediate

Hefei Yifan Approved & Submitted Formulation 合肥亿帆已获批&已申报制剂				
TA 适应领域	Product Name 产品名	Strength 规格	China 中国获批情况	Europe 欧洲注册情况
Hematologic malignancies 血液肿瘤	Plerixafor Injection 普乐沙福注射液	1.2ml:24mg	Approved in May, 2022	Ready to file 注册资料准备中
	Vincristine Sulfate Injection 硫酸长春新碱注射液	1ml:1mg	Approved in February, 2023	Ready to file 注册资料准备中
	Clofarabine Injection 氯法拉滨注射液	20ml:20mg	Approved in June, 2023	Ready to file 注册资料准备中
	Cytarabine for Injection 注射用阿糖胞苷	0.1g; 0.5g	Approved in June, 2025	Ready to file 注册资料准备中
	Carfomil for Injection 注射用卡非佐米	60mg	Est. Approval Oct. 2026	DMF not ready
First-aid 急救	Norepinephrine Bitartrate Injection 重酒石酸去甲肾上腺素注射液	1ml: 2mg	Approved in June, 2024	Ready to file 注册资料准备中
		4ml:8mg	Approved in March, 2023	PICS submitted PICS已注册
	Phenylephrine Hydrochloride Injection 盐酸去氧肾上腺素注射液	1ml:10mg	Approved in March, 2023	Ready to file 注册资料准备中
	Dopamine Hydrochloride Injection 盐酸多巴胺注射液	5ml:100mg	Approved in April, 2023	Ready to file 注册资料准备中
Gynaecology and obstetrics 妇产科	Oxytocin Injection 缩宫素注射液	10IU	Approved in March, 2024	CIS registering CIS注册中
	Oxytocin Nasal Spray 缩宫素鼻喷雾剂	5ml:200IU	Renewal in June, 2020	Ready to file 注册资料准备中
Congenital hyperinsulinism 先天性高胰岛素血症	Diazoxide Oral Suspension 二氮嗪口服混悬液	50mg/ml; 30ml	Approved in January, 2024	Ready to file 注册资料准备中

Hefei Yifan Approved & Submitted Formulation

合肥亿帆已获批&已申报制剂

TA 适应领域	Product Name 产品名	Strength 规格	China 中国获批情况	Europe 欧洲注册情况
Pain relief 镇痛	Phloroglucinol Injection 间苯三酚注射液	4ml:40mg/40µg	Approved in Jun,2024	Ready to file 注册资料准备中
Muscle relaxant 肌肉松弛药物	Methocarbamol Injection 美索巴莫注射液	10ml:1g	Approved in Aug. 2024	Ready to file 注册资料准备中
	Neostigmine Methylsulfate Injection 甲硫酸新斯的明注射液	1ml:0.5mg 2ml:1mg 4ml:2mg	Approved in November, 2024	Ready to file 注册资料准备中
Central analgesics 中枢性镇痛药	Eptazocine Hydrobromide Injection 氢溴酸依他佐辛注射液	1ml:15mg	Approved in April, 2025	DMF not ready
Gastrointestinal hemostasis 消化道止血	Famotidine Injection 法莫替丁注射液	2ml:20mg	Approved in September, 2024	Ready to file 注册资料准备中
Disease of respiratory system 呼吸系统疾病	Ambroxol HCl + Clenbuterol HCl Oral Solution 氨溴特罗口服溶液	1ml:1.5mg Ambroxol + 1µg Clenbuterol	Approved in March, 2025	DMF not ready
Chemotherapy drug 化疗药物	Epirubicin Hydrochloride for Injection 注射用盐酸表柔比星	10mg	Approved in June, 2025	DMF not ready
Vitamin 维生素类药	Vitamin K1 Injection 维生素K1注射液	0.2ml:2mg 1ml:10mg	Est. Approval September 2025	Ready to file 注册资料准备中
Antiplatelet drugs 抗血小板药	Tirofiban Hydrochloride Concentrated Solution for Injection 盐酸替罗非班注射用浓溶液	50 ml:12.5mg	Approved in June, 2023	Ready to file 注册资料准备中
Agonist 拮抗剂	Nimodipine Injection 尼莫地平注射液	50ml:10mg	Approved in April, 2024	Ready to file 注册资料准备中
Antifungal drug 抗真菌药物	Isavuconazonium Sulfate for Injection 注射用硫酸艾沙康唑	200mg	Est. Approval November, 2025	DMF not ready
Anti-infection 抗感染	Polymyxin B sulfate for injection 注射用硫酸多黏菌素B	500000 Units	Est. Approval July, 2026	DMF not ready

Fisiopharma Approved Formulation

Fisiopharma已批准制剂

Molecules 产品名称	Formualtion 剂型	Strength 规格	EU 欧洲	M.A. # 注册证号
Bupivacaine hydrochloride 盐酸布比卡因	Injection 注射剂	2.5mg/ml * 5ml 2.5mg/ml * 10ml - ampoules 5.0mg/ml * 5ml 2.5mg/ml * 10ml - ampoules	Approved 已批准	035246014 035246026 035246038 035246040
Sugammadex sodium 舒更葡糖钠	Injection 注射剂	100mg/ml - 2ml 1 vial 100mg/ml - 2ml 10 vials 100mg/ml - 5ml 1 vial 100mg/ml - 5ml 10 vials	Approved 已批准	050534015 050534039 050534027 050534041
Midazolam hydrochloride 盐酸咪达唑仑	Injection 注射剂	5mg/1ml - 1 ampoule 5mg/1ml - 5 ampoules 5mg/1ml - 10 ampoules 15mg/3ml - 1 ampoule 15mg/3ml - ampoules 15mg/3ml - 10 ampoules	Approved 已批准	037263011 037263023 037263035 037263047 037263050 037263062
Triamcinolone acetonide 醋酸曲安奈德	Injection 注射剂	40mg/1ml - 3 vials 80mg/2ml - 3 vials 80mg/2ml - 5 ampoules	Approved 已批准	034262016 034262028 034262030
Tobramycin 妥布霉素	Injection 注射剂	100mg/2ml 150mg/2ml	Approved 已批准	035132036 035132048
Water for injection 注射用水	Injection 注射剂	10ml - 10 ampoules	Approved 已批准	031405246
Chloramphenicol sodium succinate 氯霉素琥珀酸钠	Injection 注射剂	1g/10ml - 1 vial powder + 1 ampoule solvent	Approved 已批准	031414016
Chloramphenicol sodium succinate 氯霉素琥珀酸钠	Injection 注射剂	1g - 10 vials powder	Approved 已批准	031414028

Fisiopharma Approved Formulation Fisiopharma已批准制剂				
Molecules 产品名称	Formualtion 剂型	Strength 规格	EU 欧洲	M.A. # 注册证号
Erythromycin Lactobionate 乳糖酸红霉素	Injection 注射剂	1g/20ml - 1 vial powder + 1 ampoule 20 ml solvent 500mg/10ml - 1 vial powder + 1 ampoule solve	Approved 已批准	031421023 031421011
Furosemide 呋塞米	Injection 注射剂	20mg/2ml 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031422013 031422025 031422037 031422049
Gentamicin sulphate 硫酸庆大霉素	Injection 注射剂	80mg/2ml 1 ampoule 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031423027 031423066 031423078 031423080
	Injection 注射剂	40mg/2ml 1 ampoule 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031423015 031423039 031423041 031423054
Lidocaine hydrochloride 盐酸利多卡因	Injection 注射剂	200mg/10ml - 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031425022 031425061 031425073 031425085
	Injection 注射剂	50mg/5ml - 5 ampoules 10 ampoules 50 ampoules 100 ampoules	Approved 已批准	031425010 031425034 031425046 031425059
Dobutamine hydrochloride 盐酸多巴酚丁胺	Injection 注射剂	250mg/20ml - 1 vial	Approved 已批准	033609013
Vancomycin hydrochloride 盐酸万古霉素	Injection 注射剂	500mg - 10 vials 1g - 1 vial	Approved 已批准	034634030 034634028

Fisiopharma Approved Formulation Pharmatex Italia已批准制剂				
Molecules 产品名称	Formualtion 剂型	Strength 规格	EU 欧洲	M.A. # 注册证号
Amikacin sulphate 硫酸阿米卡星	Injection 注射剂	500mg/2ml - 10 ampoules	Approved 已批准	024459137
Cefotaxime 头孢噻肟	Injection 注射剂	1 vial powder of 500mg+solv 2ml 1 vial powder of 1g+solv 4ml 1 vial powder of 1g+solv 4ml with lidocaine 1 vial powder of 2g+solv 10 ml	Approved 已批准	035068016 035068028 035068030 035068042
Heparin sodium 肝素钠	Injection 注射剂	5000 UI/1ml10 ampoules 25000 UI/5ml 10 ampoules 25000 UI /5ml 1 vials 10 vials	Approved 已批准	034692032 034692020 034692018 034692044
Potassium aspartate 天冬氨酸钾	Injection 注射剂	10 mEq/10ml 30 mEq/10ml	Approved 已批准	036918011 036918023
Pamidronic acid 帕米膦酸	Injection 注射剂	30mg/10ml 60mg/10ml 90mg/10ml	Approved 已批准	036645024 036645036 036645048
Piperacillin 哌拉西林	Injection 注射剂	1g vial + 2ml ampoule 2g vial + 4ml ampoule 4g - 10 vials	Approved 已批准	033958012 033958024 033958036
Piperacillin/tazobactam 哌拉西林/他唑巴坦	Injection 注射剂	2g+250mg/4ml - vial + ampoule 4g+500mg -1 vial 4g+500mg -10 vials	Approved 已批准	038558019 038558021 038558033
Vancomycin hydrochloride 盐酸万古霉素	Injection 注射剂	500mg - 1 vial 500mg - 10 vials 1g - 1 vial	Approved 已批准	034632012 034632036 034632024
Triamcinolone acetonide 醋酸曲安奈德	Injection 注射剂	40mg/1ml - 3 vials 80mg/2ml - 3 vials	Approved 已批准	033919010 033919022

Approved Herbal Medicine 已获批中成药		
Product Name 产品名	Strength 规格	Indication 适应症
Oral Arsenic Realgar-Indigo Naturalis Formula 复方黄黛片	每片重0.27g, 每瓶装100片	Clear heat and detoxifying, supplementing Qi and producing blood. For initial treatment of acute myeloid leukaemia 清热解毒，益气生血。用于初治的急性早幼粒细胞白血病
Compound Yinhua Jiedu Granules 复方银花解毒颗粒	每袋15g, 6袋/盒	Disperse wind, clear heat and detoxify by dispelling pathogenic factors through the exterior part of the body. Used for common cold and influenza associated with wind-heat syndrome. Relief of symptoms including fever, slight aversion to wind, headache, stuffy running nose, cough, sore throat, whole body aching pain, white or yellow tongue coating with faintly visible tongue surface, superficial and rapid pulse 疏风解表，清热解毒。用于普通感冒、流行性感冒属风热证，症见：发热，微恶风，头痛，鼻塞流涕，咳嗽，咽痛，全身酸痛，苔薄白或微黄，脉浮数
Maqin Xiaoke Granules 麻芩消咳颗粒	每袋8g, 6袋/盒	Clear lung fire and resolve phlegm, suppress cough and to calm panting. Used for acute bronchitis and acute episode of chronic bronchitis with syndrome of phlegm-heat obstructing the lung. Relief of symptoms including cough, dyspnea, expectoration of yellow or thick sputum, fever, dry mouth, yellow greasy tongue coating, reddened tongue, etc 清肺化痰，止咳平喘。用于急性支气管炎、慢性支气管炎急性发作属痰热郁肺证，症见：咳嗽、喘息、痰黄或稠厚、发热、口干、苔黄腻、舌红等症
Piminxiao Capsules 皮敏消胶囊	每粒装0.4g, 10粒/板×2板/盒; 12粒/板×2板/盒	Dispel wind and remove dampness, clear heat and detoxify, cool blood and relieve itching, for acute and chronic urticaria, acute eczema is wind-heat syndrome or wind-heat with dampness syndrome 祛风除湿，清热解毒，凉血止痒，用于急慢性荨麻疹、急性湿疹属风热证或风热挟湿证者
Ginkgo Leaf Pills 银杏叶丸	每瓶装0.2g（含总黄酮醇苷19.2mg, 萜类内酯4.8mg），0.2g/瓶×6瓶/板×2板/盒	To promote blood circulation, remove stasis, and free the collateral vessels. It is used for chest impediment, heart pain, wind stroke, hemiplegia, and sluggish speech caused by blood stasis obstructing the collaterals; stable angina pectoris of coronary heart disease and cerebral infarction with the above syndromes 活血化瘀通络。用于瘀血阻络引起的胸痹、心痛、中风、半身不遂、舌强语蹇，冠心病稳定型心绞痛、脑梗塞见上述证候者
Chushi Zhiyang Ointment 除湿止痒软膏	每支装10g; 每支装20g	Clearing heat and removing dampness, dispelling wind and relieving itch. It is used for the auxiliary treatment of acute and subacute eczema which is damp-heat or damp-resistance type 清热除湿，祛风止痒。用于急性、亚急性湿疹证属湿热或湿阻型的辅助治疗

API List 原料药清单			
Molecules 产品名称	CAS No.	TA 适应领域	China 中国
Melatonin 褪黑素	73-31-4	API for drug for regulating sleep and maintain a sleep cycle 调节睡眠（口服制剂）	可售 Marketable (全国独家)
Diazoxide 二氮嗪	364-98-7	API for medicine for treating congenital hyperinsulinemic hypoglycemia (CHI) and emergency treatment of hypertensive crisis 先天性高胰岛素性低血糖血症；高血压危象的急救（口服或注射剂）	可售 Marketable (印度已获批)
Norepinephrine Bitartrate 重酒石酸去甲肾上腺素	69815-49-2	API for medicine for excessive anesthesia, shock, heart failure, and other critical illnesses 心源性休克、麻醉过量、失血性休克、心力衰竭、中毒性休克等危急重症（注射剂）	可售 Marketable (新加坡DMF)
Azacytidine 阿扎胞苷	320-67-2	API for drug for leukemia, such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, etc 白血病，如急性髓系白血病、急性淋巴细胞白血病、慢性粒细胞白血病急变期等（注射剂）	可售 Marketable
Cytarabine 阿糖胞苷	147-94-4	API for drug for leukemia, such as acute myeloid leukemia, chronic myeloid leukemia 急性髓系白血病、慢性髓系白血病（急变期）的诱导缓解和维持治疗（注射剂）	可售 Marketable
Emedastine Difumarate 富马酸依美斯汀	87233-62-3	API for medicine as antihistaminic, H1-receptor; asthma prophylactic; anti-allergic 过敏性鼻炎和荨麻疹（口服缓释胶囊）	可售 Marketable
Plerixafor 普乐沙福	110078-46-1	API for drug for non-Hodgkinlymphoma 非霍奇金淋巴瘤和多发性骨髓瘤（注射剂）	可售 Marketable
Clofarabine 氯法拉滨	123318-82-1	API for drug as broad-spectrum anti-tumor drugs 广谱抗肿瘤（注射剂）	可售 Marketable
Oxytocin solid 缩宫素固体	50-56-6	API for drug for uterine contraction 子宫出血；了解胎盘储备功能（激惹试验）；催乳和促进产妇生产（注射剂）	可售 Marketable
Phloroglucinol dihydrate 二水合间苯三酚	6099-90-7	API for drug for smoothing muscle spasmolysis 平滑肌解痉（注射剂）	可售 Marketable

API List 原料药清单			
Molecules 产品名称	CAS No.	TA 适应领域	China 中国
1,3,5-Trimethoxybenzene *间苯三酚三甲醚	621-23-8	Intermediate for medicine and organic synthesis 平滑肌解痉（注射剂）	可售 Marketable
Eptazocine hydrobromide 氢溴酸依他佐辛	72150-17-5	API for drug for relieving cancer pain and postoperative pain 癌痛及手术后疼痛（注射剂）	可售 Marketable
Dapoxetine Hydrochloride 盐酸达泊西汀	129938-20-1	API for drug for premature ejaculation 男性早泄（口服制剂）	可售 Marketable
Vindesine Sulfate 硫酸长春地辛	59917-39-4	Mainly used for the treatment of non-small cell lung tumor, small cell lung tumor, malignant lymphoma, esophageal tumor, breast tumor and malignant melanoma and other malignant tumors: It can also treat children with other drug-resistant acute lymphoblastic leukemia, chronic myeloid leukemia in the acute stage, and malignant lymphoma that does not respond to treatment 主要用于治疗非小细胞肺癌、小细胞肺癌、恶性淋巴瘤、食管瘤、乳腺瘤及恶性黑色素瘤等恶性肿瘤: 亦可以治疗其它药物耐药的急性淋巴细胞白血病的儿童患者、慢性粒细胞白血病急变期、对治疗无反应的恶性淋巴瘤	在研 being developed
Glyceryl phenylbutyrate 苯丁酸甘油酯	611168-24-2	Urea cycle disorders (UCDs) that cannot be controlled by limiting protein intake and/or amino acid supplementation alone 不能通过限制蛋白质的摄入和/或单纯补充氨基酸控制的尿素循环障碍（UCDs）	在研 being developed
Budesonide 布地奈德	51333-22-3	API for drug for respiratory disease 呼吸系统甾体激素药（吸入制剂）	在研 being developed
Difelikefalin 醋酸地非法林	1024828-77-0	Itching caused by hemodialysis, renal disease-related itching, chronic kidney disease with moderate to severe itching 血液透析引起的瘙痒、肾脏疾病相关性瘙痒、慢性肾病伴中重度瘙痒（注射剂）	在研 being developed
Desonide 地奈德	638-94-8	API for drug for dermatitis 接触性皮炎、神经性皮炎、脂溢性皮炎、湿疹（外用制剂）	在研 being developed

Excipients List 辅料清单				
Product Name 产品名	CAS No.	Remark on usage 适应领域	Status 产品状态	Registration No. 备案编号
1-Hexadecanol 十六醇	36653-82-4	Used as detergent, surfactants, lubricants,-pharmaceutical intermediates, spices and daily chemical raw materials 乳化剂、软膏基质、消泡剂	marketable 可售	F20160059 湘/Xiang(A)
1-Octadecanol 十八醇	112-92-5	Used as anti-foam agent, lubricant, viscosity agent, builder, and chemical raw material 分散剂、乳化剂、消泡剂、润滑剂	marketable 可售	F20160060 湘/Xiang(A)
Cetearyl alcohol 十六十八醇	8005-44-5	Used as anti-foam agent, lubricant, viscosity agent, builder, and chemical raw material 润滑剂、乳化剂、增黏剂	marketable 可售	F20120002 湘/Xiang(A)
Glyceryl Mono-and Distearate 单、双硬脂酸甘油酯	/	Used as a skin lubricant and imparts a pleasant skin feel 润滑剂、乳化剂、抗菌剂、软膏基质	marketable 可售	F20110007 湘/Xiang(A)
Stearic acid 硬脂酸	57-11-4	Used as emulsifiers, ointment matrices, lubricants, defoamers 乳化剂、软膏基质、润滑剂、消泡剂	marketable 可售	F20070016 湘/Xiang(A)
Methylparaben 羟苯甲酯	99-76-3	Inactive ingredients for drugs as bacteriostat 抑菌剂（外用制剂）	marketable 可售	F20230000499（I）
Ethyl-hydroxybenzoate 羟苯乙酯	118-61-6	Inactive ingredients for drugs as bacteriostat 抑菌剂（外用制剂）	marketable 可售	F20230000500（I）
Propylparaben 羟苯丙酯	94-13-3	Inactive ingredients for drugs as bacteriostat 抑菌剂（外用制剂）	marketable 可售	F20230000502（I）
Butylparaben 羟苯丁酯	94-26-8	Inactive ingredients for drugs as bacteriostat 抑菌剂（外用制剂）	marketable 可售	F20230000501（I）
PEG4000 聚乙二醇4000	25322-68-3	Increase drug solubility, reduce drug toxicity improve drug stability, etc 增加药物溶解度、降低药物毒性、改善药物稳定性等（口服和外用制剂）	marketable 可售	F20220000575（I）

Excipients List 辅料清单				
Product Name 产品名	CAS No.	Remark on usage 适应领域	Status 产品状态	Registration No. 备案编号
PEG6000 聚乙二醇6000	25322-68-3	Increase drug solubility, reduce drug toxicity, improve drug stability, etc 增加药物溶解度、降低药物毒性、改善药物稳定性等（口服和外用制剂）	marketable 可售	F20220000579（I）
Paraffin 石蜡	8002-74-2	Inactive ingredients for drugs as ointment matrix, coating material 软膏基质和包衣材料	marketable 可售	F20230000191（I）
Microcrystalline Wax 微晶蜡	8001-75-0	Inactive ingredients for drugs as sustained release carrier, coating material 包衣剂、控制释放载体	marketable 可售	F20230000447（I）
Palmitic acid 棕榈酸	1957-10-3	Inactive ingredients for drugs as ointment matrix, lubricant 润滑剂和软膏基质，广泛用于口服和外用制剂	marketable 可售	F20230000158（I）
Lauric acid 月桂酸	143-07-7	Inactive ingredients for drugs as absorption promoter, stabilizer 局部渗透和透皮吸收、直肠吸收、口腔输送和肠道吸收的促进剂；稳定水包油乳液	marketable 可售	F20230000157（I）
Myristic acid 肉豆蔻酸	544-63-8	Inactive ingredient for drugs as defoamer and ointment matrix 消泡剂和软膏基质，用于口服和外用药物制剂	marketable 可售	F20240000065（I）
Urea 尿素	57-13-6	Ingredient of ointments for skin disease 手足皸裂（外用制剂）	marketable 可售	F20240000034（I）
Glyceryl Monostearate 单硬脂酸甘油酯	31566-31-1	Inactive ingredient for drugs as pearlescent dispersant, solubilizer, lubricant 表面活性剂、乳化剂、分散剂、消泡剂	marketable 可售	F20230000439（I）
Sucrose octasulfate triethylammonium 蔗糖八硫酸酯三乙胺	869561-07-9	Used in liposomes, it can improve the stability of drugs, reduce the probability of hydrolysis, and extend the half-life of drugs in vivo 用于脂质体中，可提高药物的稳定性，降低被水解的概率，延长药物体内半衰期。（脂质体制剂）	marketable 可售	F20230000561（I）

Excipients List 辅料清单				
Product Name 产品名	CAS No.	Remark on usage 适应领域	Status 产品状态	Registration No. 备案编号
Gallic acid 没食子酸	149-91-7	Inactive ingredients for drugs as chelating agents and antioxidants 螯合剂和抗氧化剂	marketable 可售	F20240000526（I）
Benzoic Acid 苯甲酸	65-85-0	Preservative, spice and etc. 防腐剂、香料等	marketable 可售	F20240000459（I）
Fumaric Acid 富马酸	110-17-8	Acidifying agent, flavoring agent, antioxidant agent 酸化剂、增香剂、抗氧化助剂	marketable 可售	F20240000472（I）
PEG300 （for injection） 聚乙二醇300（注射用）	25322-68-3	Inactive ingredient for drugs as solvents, cosolvents 增溶剂（注射剂）	being developed 在研	/
PEG400 聚乙二醇400（注射用）	25322-68-3	Inactive ingredient for drugs as solvents, cosolvents, dispersants, emulsifiers 溶剂、助溶剂、分散剂、乳化剂、润滑剂、粘合剂	marketable 可售	/
Glycocholic acid 甘氨酸酸	475-31-0	Carrier of insoluble drugs 难溶性药物的载体	being developed 在研	/
Anhydrous Calcium Hydrogen Phosphate 无水磷酸氢钙	7757-93-9	Diluents for hydrophobic drug tablets and capsules 药用辅料,憎水药物片剂和胶囊剂的稀释剂（口服制剂）	being developed 在研	/
Calcium Hydrogen Phosphate Dihydrate 二水磷酸氢钙	7789-77-7	Diluents for hydrophobic drug tablets and capsules 药用辅料,憎水药物片剂和胶囊剂的稀释剂	being developed 在研	/
DSPC 二硬脂酰磷脂酰胆碱	816-94-4	Inactive ingredient, commonly used in liposomes 脂质体常用辅料（脂质体）	being developed 在研	/
DSPS 二硬脂酰磷脂酰丝氨酸（钠盐）	321595-13-5	Inactive Ingredient of ultrasound contrast agents 脂质体常用辅料（脂质体）	being developed 在研	/

Intermediate List
中间体清单

Molecules 产品名称	CAS No.	TA 适应领域	CHINA 中国
Carfilzomib Intermediate 卡非佐米中间体	868540-16-3	API for drug for multiple myeloma 多发性骨髓瘤（注射剂）	可售 Marketable
Ixazomib citrate Intermediate 枸橼酸伊沙佐米中间体	1201903-02-7	API for drug for multiple myeloma 多发性骨髓瘤（口服制剂）	在研 being developed
Venetoclax Intermediate 维奈克拉中间体	1235865-77-6	In combination with azacitidine for the treatment of newly diagnosed adult patients with acute myeloid leukemia aged 75 and above who are not suitable for strong induction chemotherapy due to comorbidities 与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者（口服制剂）	在研 being developed
Cedazuridine Intermediate 西达尿苷	1141397-48-9	Myelodysplastic syndrome, acute myeloid leukemia, newly diagnosed acute myeloid leukemia 骨髓增生异常综合征、急性髓系白血病、新诊断急性髓系白血病（口服制剂）	在研 being developed
Selumetinib bisulfate Intermediate 硫酸氢司美替尼中间体	606144-05-2	Treatment of pediatric patients with type 1 neurofibromatosis (NF1) who are 3 years old and above with symptoms and inoperable plexus neurofibromatosis (PN) 用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤(PN)的1型神经纤维瘤病(NF1)儿科患者的治疗。（口服制剂）	在研 being developed
Ribociclib succinate Intermediate 琥珀酸瑞波西利中间体	2762182-61-4	Applicable to hormone receptor (HR) -positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced or metastatic breast cancer, and is used in combination with aromatase inhibitors as the initial endocrine therapy for female patients 适用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性局部晚期或转移性乳腺癌，与芳香化酶抑制剂联合用药作为女性患者的初始内分泌治疗。	在研 being developed
Dotinurad Intermediate 多替诺雷中间体	1285573-44-5	Treatment of gout and hyperuricemia in adults 用于治疗成人痛风及高尿酸血症（口服制剂）	在研 being developed
Belumosudil Mesylate Intermediate 甲磺酸贝舒地尔中间体	911417-26-0	Treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older who have failed prior systemic therapy(ies), including inadequate response to cortico-steroids or other systemic treatments 用于治疗对糖皮质激素或其他系统治疗应答不充分的 12 岁及以上慢性移植物抗宿主病患者（口服制剂）	在研 being developed

Intermediate List
中间体清单

Molecules 产品名称	CAS No.	TA 适应领域	CHINA 中国
Difamilast Intermediate 地法米斯特中间体	1574285-43-0	Treatment of mild to moderate atopic dermatitis in patients aged 3 months and older 3个月及以上轻至中度特应性皮炎（外用制剂）	在研 being developed
Niraparib Tosylate Intermediate 甲苯磺酸尼拉帕利中间体	1476776-84-7	1) Maintenance treatment of adult patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy 2) Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy 1) 铂敏感的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者在含铂化疗达到完全缓解或部分缓解后的维持治疗； 2) 晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者对一线含铂化疗达到完全缓解或部分缓解后的维持治疗（口服制剂）	在研 being developed

03 | Synthetic Biology
Product List 亿帆合成生物产品

CAS No.	Product Name 产品名	Application 功效和应用领域
137-08-6	VitaminB5/CalciumPantothenate USP/BP/EP/IP 维生素B ₅ /泛酸钙	Widely used in food and animal feed, multi-vitamin capsule, tablets, energy drinking etc
58-56-0	VitaminB6 / Pyridoxine Hydrochloride 维生素B ₆ 盐酸吡哆醇	Widely used in food and feed industry Used as a nutritional supplement and enhancer in the food industry In livestock and poultry breeding, this product is used as a vitamin feed additive
41263-94-9 157574-76-0	Human milk oligosaccharide: 2'-FL 6'-SL 母乳低聚糖 / HMOs	Has various physiological functions such as improving gut microbiota, regulating immunity, and promoting neural development Children's formulated milk, infant formula, complementary foods for infants and young children, infant formula foods for special medical purposes, functional foods, and the fields of pharmaceuticals and health products
81-13-0	D-Panthenol USP/BP/EP/IP D-Panthenol 75%W D-Panthenol 50%P D-Panthenol 50%W D-泛醇	Pro-Vitamin B5 series / 维生素原B5系列 D-Panthenol is the provitamin of D-Pantothenic acid (Vitamin B5), which plays a key role in human intermediary metabolism. As an active ingredient in cosmetics, such as skin care and hair care products, D-panthenol is a part of Coenzyme A - Role in the skin: 1. Deep-penetrating moisturizer 2. Stimulates epithelization 3. Has wound-healing effect 4. Has an anti-inflammatory effect - Role in the hair: 1. Long-lasting moisturizer 2. Prevents hair damage 3. Thickens hair 4. Improves luster and sheen - Role in nail care: 1. Improves hydration 2. Imparts flexibility
16485-10-2	DL-Panthenol USP DL-Panthenol 50%W DL-泛醇	
667-83-4	D-Panthenyl Ethyl Ether D -泛醇乙醚	
667-84-5	DL-Panthenyl Ethyl Ether DL -泛醇乙醚	
599-04-2	D-(-)-Pantolactone D - 泛解酸内酯	Ingredient for cosmetics, intermediate for Calcium Pantothenate, D/DLPanthenol, Pantethine, etc
109-78-4	3-Hydroxypropionitrile 3 -羟基丙腈	Preparation of luminescent substrates of luminescent reagents, electrolyte additives for new energy batteries
156-87-6	3-Aminopropanol 3 - 氨基丙醇	Mainly for synthesis of D/DL-Panthenol, and to synthesize cyclophosphamide, cardiac and other drugs